Citigroup Inc Tyra Biosciences, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Citigroup Inc holds 14,667 shares of TYRA stock, worth $233,938. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,667

Previous 4,433 230.86%

Holding current value

$233,938

Previous $70,000 391.43%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$16.7 - $24.36 $170,907 - $249,300	10,234 Added 230.86%	14,667 $344,000
Q2 2024 Aug 12, 2024	SELL	$14.45 - $20.22 $38,624 - $54,048	-2,673 Reduced 37.62%	4,433 $70,000
Q1 2024 May 10, 2024	BUY	$11.61 - $20.0 $58,920 - $101,500	5,075 Added 249.88%	7,106 $116,000
Q4 2023 Feb 09, 2024	BUY	$11.01 - $14.95 $22,152 - $30,079	2,012 Added 10589.47%	2,031 $28,000
Q3 2023 Nov 09, 2023	SELL	$13.15 - $16.08 $54,519 - $66,667	-4,146 Reduced 99.54%	19 $0
Q2 2023 Aug 10, 2023	BUY	$11.99 - $17.51 $49,938 - $72,929	4,165 New	4,165 $70,000
Q4 2022 Feb 09, 2023	SELL	$5.68 - $8.81 $630 - $977	-111 Reduced 55.5%	89 $0
Q3 2022 Nov 10, 2022	SELL	$6.61 - $12.42 $4,851 - $9,116	-734 Reduced 78.59%	200 $2,000
Q2 2022 Aug 10, 2022	BUY	$5.26 - $11.19 $2,498 - $5,315	475 Added 103.49%	934 $7,000
Q1 2022 May 12, 2022	SELL	$10.03 - $14.09 $27,141 - $38,127	-2,706 Reduced 85.5%	459 $5,000
Q4 2021 Feb 10, 2022	BUY	$12.23 - $31.35 $33,326 - $85,428	2,725 Added 619.32%	3,165 $45,000
Q3 2021 Nov 10, 2021	BUY	$16.91 - $26.0 $7,440 - $11,440	440 New	440 $8,000

Others Institutions Holding TYRA

# of Institutions

Shares Held

43.5M

Call Options Held

353K

Put Options Held

1.1K

View Full List

About Tyra Biosciences, Inc.

Ticker TYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,973,600
Market Cap $669M
Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...

More about TYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account